Search Login Register

sunitinib (Sutent) Summary

Description: inhibits VEGF-R2 and PDGF-Rbeta tyrosine kinase; has antineoplastic activity; structure in first source

Also Known As: Sutent; SU 11248; SU011248; sunitinib malate; 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide Show All >>

Networked: 2234 relevant articles (323 outcomes, 603 trials/studies) for this Drug

Key Diseases for which sunitinib is Relevant

  1. Renal Cell Carcinoma (Grawitz Tumor) : 129 outcomes 187 studies in 890 results
  2. Neoplasms (Cancer) : 86 outcomes 143 studies in 740 results
  3. Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) : 25 outcomes 25 studies in 192 results
  4. Kidney Neoplasms (Kidney Cancer) : 19 outcomes 20 studies in 122 results
  5. Neoplasm Metastasis (Metastasis) : 18 outcomes 26 studies in 168 results
Show All >>

Drugs Related to sunitinib

  1. sorafenib (BAY 43-9006)
  2. Protein-Tyrosine Kinases (Tyrosine Kinase)
  3. imatinib (Gleevec)
  4. bevacizumab
  5. everolimus
  6. Phosphotransferases (Kinase)
  7. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
  8. Interferon-alpha (Interferon Alfa)
  9. temsirolimus
  10. Interferons
Show All >>

Therapies Related to sunitinib

  1. Drug Therapy (Chemotherapy)
  2. Heterologous Transplantation (Xenotransplantation)
  3. Radiotherapy
  4. Nephrectomy
  5. Neoadjuvant Therapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.